Molecular Imaging: PET, SPECT, Tracers, and Theranostics Explained

Molecular imaging visualizes biological processes at the cellular and molecular level rather than anatomical structure. Where a CT scan shows that a mass exists and measures it, molecular imaging shows what that mass is doing: whether it is metabolically active, whether it expresses a particular receptor, whether it is responding to treatment. The distinction matters clinically because disease frequently produces molecular change before it produces structural change, and because treatment decisions increasingly depend on whether a tumor expresses a specific molecular target.

The technique works by introducing a tracer, a molecule designed to bind to a particular biological target, labeled with something the scanner can detect. Where the tracer accumulates, the scanner sees signal. This guide covers the modalities that perform molecular imaging, the tracers that make it specific, the clinical applications where it has changed practice, and theranostics, which uses the same molecular targeting for treatment as well as diagnosis.

For the broader landscape of imaging techniques including the anatomical modalities, see imaging modalities.

Molecular imaging compared to anatomical imaging

Anatomical imaging answers questions about structure. X-ray, CT, MRI, and ultrasound produce images of tissue based on physical properties: density for X-ray and CT, proton behavior in a magnetic field for MRI, acoustic reflection for ultrasound. These techniques show size, shape, position, and structural abnormality.

Molecular imaging answers questions about function and biology. It shows metabolic rate, receptor density, protein deposition, blood flow at the tissue level, and cell proliferation. The image reflects where a targeted tracer accumulated rather than what the tissue looks like.

The practical consequence is that the two answer different clinical questions and are frequently used together. A CT identifies a pulmonary nodule and measures it. A PET scan indicates whether that nodule is metabolically active in a pattern consistent with malignancy. Neither alone gives the full picture, which is why hybrid PET/CT and PET/MRI systems acquire both in a single session and display them fused.

Molecular imaging also detects disease earlier in some contexts. Amyloid deposition in the brain precedes structural atrophy by years. Treatment response in tumors appears as reduced metabolic activity before the tumor shrinks measurably. Where the clinical question is about biology rather than anatomy, molecular imaging reaches an answer that structural imaging cannot.

The modalities

Positron emission tomography

PET uses tracers labeled with positron-emitting isotopes, most commonly fluorine-18, gallium-68, carbon-11, or copper-64. When the isotope decays, it emits a positron that travels a short distance in tissue before encountering an electron. The two annihilate, converting their mass into two 511 keV photons that travel in opposite directions.

The scanner detects these photon pairs in coincidence, meaning it registers only events where two detectors on opposite sides fire within a few nanoseconds of each other. This coincidence requirement is what gives PET its spatial precision, since the annihilation event must have occurred somewhere along the line connecting the two detectors. Reconstructing across millions of such events produces a three-dimensional map of tracer distribution.

PET offers the highest sensitivity of any clinical imaging technique, detecting tracer concentrations in the picomolar range. That sensitivity is what allows imaging of receptor binding and metabolic processes that exist at very low concentrations in tissue.

Single photon emission computed tomography

SPECT uses tracers labeled with isotopes that emit single gamma photons directly, most commonly technetium-99m, iodine-123, or indium-111. A gamma camera rotates around the patient, collecting projections that are reconstructed into a three-dimensional distribution.

Because SPECT detects single photons rather than coincident pairs, it requires physical collimation to determine the direction each photon came from. The collimator absorbs the majority of emitted photons, which is the primary reason SPECT sensitivity is lower than PET.

SPECT retains significant clinical roles despite that limitation. Technetium-99m is produced from a generator that can sit in a hospital’s nuclear medicine department, has a convenient six-hour half-life, and costs substantially less than cyclotron-produced PET isotopes. For high-volume applications like myocardial perfusion imaging and bone scanning, that economics matters.

PET vs SPECT

	PET	SPECT
Detection	Coincident photon pairs from positron annihilation	Single gamma photons with physical collimation
Sensitivity	Higher, picomolar tracer concentrations	Lower, collimator absorbs most photons
Spatial resolution	Approximately 4 to 5 mm clinically	Approximately 8 to 12 mm clinically
Quantification	Absolute, expressed as standardized uptake value	Relative, absolute quantification more difficult
Isotope supply	Cyclotron or generator, shorter half-lives	Generator-produced, longer half-lives
Relative cost	Higher	Lower
Typical uses	Oncology staging, neurology, cardiac viability	Myocardial perfusion, bone scan, thyroid, renal

The choice between them is usually settled by the tracer rather than by scanner preference. If the molecular target has a validated PET tracer, the study is a PET study. Myocardial perfusion is the main context where both are routinely used and the decision is genuinely open, with PET offering better quantification and lower radiation dose, and SPECT offering wider availability.

Molecular MRI

MRI is primarily anatomical, but targeted contrast agents extend it into molecular territory. Agents built on iron oxide nanoparticles or gadolinium chelates can be functionalized to bind specific molecular markers, producing signal change where the target is present.

MRI brings spatial resolution that nuclear techniques cannot match and involves no ionizing radiation. Its limitation is sensitivity: the concentration of contrast agent required to produce a detectable signal change is orders of magnitude higher than the tracer concentration PET can detect. This constrains molecular MRI to targets present at relatively high density.

Hyperpolarized MRI, which uses carbon-13 labeled substrates prepared to have dramatically enhanced signal, addresses part of this limitation and allows real-time imaging of metabolic conversion. Clinical use remains concentrated in research settings.

Optical imaging

Fluorescence, bioluminescence, and photoacoustic techniques use light rather than ionizing radiation or magnetic fields. Tissue penetration is limited to a few centimeters, which rules out imaging of deep structures but suits intraoperative and endoscopic applications well.

Fluorescence-guided surgery is the clinical application with the clearest traction. A tumor-targeting fluorescent agent administered before surgery allows the surgeon to see tumor margins directly in the operative field, which addresses the persistent problem of determining margins by inspection and palpation alone.

Tracers: what makes molecular imaging molecular

The scanner detects signal. The tracer determines what that signal means. Molecular imaging’s clinical range is defined almost entirely by which tracers are available and validated.

FDG, fluorodeoxyglucose labeled with fluorine-18, is a glucose analogue taken up by metabolically active cells and trapped intracellularly. Because many tumors have elevated glucose metabolism, FDG has broad oncological utility across staging, restaging, and treatment response assessment. Its limitation is specificity: inflammation and infection also take up FDG, and some tumor types, including prostate cancer and well-differentiated neuroendocrine tumors, show poor uptake.

PSMA tracers target prostate-specific membrane antigen, a protein expressed at high density on prostate cancer cells. Gallium-68 PSMA-11 and the fluorine-18 agents piflufolastat and flotufolastat are the clinical examples. PSMA PET detects prostate cancer recurrence at PSA levels where conventional imaging shows nothing, which has changed management in biochemical recurrence substantially.

Somatostatin receptor tracers, including gallium-68 DOTATATE and copper-64 DOTATATE, target receptors expressed by neuroendocrine tumors. These tumors are frequently FDG-negative, so somatostatin receptor imaging addresses a gap that FDG cannot.

Amyloid tracers including florbetapir, flutemetamol, and florbetaben bind beta-amyloid plaque in the brain. Tau tracers including flortaucipir bind neurofibrillary tangles. Both have become central to Alzheimer’s diagnosis and to trials of disease-modifying therapy, where confirming target pathology before enrollment is now standard.

Perfusion tracers including technetium-99m sestamibi and tetrofosmin for SPECT, and rubidium-82 and nitrogen-13 ammonia for PET, assess myocardial blood flow. These underpin the cardiac applications covered in nuclear cardiology.

FAP inhibitors, targeting fibroblast activation protein in the tumor stroma, are among the most active areas of tracer development. They show uptake across tumor types where FDG performs poorly, though clinical validation is ongoing rather than settled.

Tracer availability and regulatory status vary by jurisdiction. Verify current approval status against the relevant national regulator before relying on any specific agent in clinical planning.

Clinical applications

Oncology

Oncology accounts for the majority of clinical molecular imaging volume, across four roles.

Staging establishes disease extent at diagnosis. FDG PET/CT frequently identifies metastatic disease that conventional imaging missed, which changes the treatment plan from curative-intent local therapy to systemic treatment.

Restaging and response assessment determine whether treatment is working. Metabolic response typically precedes anatomical response, so PET can identify treatment failure earlier than size-based criteria. Response frameworks including PERCIST and Deauville criteria for lymphoma formalize this.

Recurrence detection is where PSMA PET has had the largest recent impact. A patient with rising PSA after prostatectomy previously faced conventional imaging that usually showed nothing, leaving treatment decisions to be made without knowing where disease was. PSMA PET localizes recurrence at low PSA levels, allowing targeted salvage treatment rather than empirical systemic therapy.

Patient selection for targeted therapy is the newest role, and the one that connects to theranostics below. If a therapy targets a specific molecular structure, imaging that structure identifies who will respond.

Neurology

Amyloid and tau PET have moved from research into clinical use as disease-modifying Alzheimer’s therapies have arrived. These agents require confirmed amyloid pathology before treatment, so imaging has become a gatekeeper for therapy access rather than a purely diagnostic tool.

FDG PET shows characteristic patterns of regional hypometabolism that help differentiate dementia subtypes. Dopamine transporter SPECT distinguishes Parkinsonian syndromes from essential tremor and other conditions with overlapping presentation.

In epilepsy, interictal FDG PET identifies hypometabolic regions that help localize seizure focus during presurgical evaluation, complementing EEG and structural MRI.

Cardiology

Myocardial perfusion imaging assesses blood flow at rest and under stress to identify ischemia and infarction. FDG PET assesses myocardial viability, distinguishing hibernating myocardium that will recover function after revascularization from scar that will not, which directly determines whether revascularization is worthwhile.

Cardiac sarcoidosis and infective endocarditis assessment are growing applications, both using FDG uptake patterns after dietary preparation designed to suppress normal myocardial glucose uptake.

The full clinical picture is covered in nuclear cardiology.

Infection and inflammation

Labeled leukocyte imaging localizes infection where its site is unclear. FDG PET identifies inflammatory foci in fever of unknown origin, vasculitis, and suspected prosthetic joint or vascular graft infection. The overlap between infection and malignancy on FDG imaging is a known limitation requiring clinical correlation.

Theranostics

Theranostics pairs a diagnostic tracer with a therapeutic agent that targets the same molecular structure. The imaging study identifies patients whose disease expresses the target, and the therapeutic version delivers radiation directly to those sites. The same targeting molecule is used for both, with the diagnostic isotope swapped for a therapeutic one.

The logic differs fundamentally from conventional systemic therapy. Rather than treating and then imaging to see whether it worked, theranostics images first to determine whether treatment will reach its target at all. Patients whose tumors do not express the target are identified before treatment rather than after.

Lutetium-177 DOTATATE treats gastroenteropancreatic neuroendocrine tumors. Patients are selected by somatostatin receptor PET showing sufficient uptake, then treated with the lutetium-177 labeled version of the same somatostatin-targeting molecule.

Lutetium-177 PSMA-617 treats metastatic castration-resistant prostate cancer. PSMA PET establishes that the tumor expresses PSMA, and the therapeutic agent delivers beta radiation to PSMA-expressing cells throughout the body.

Radioactive iodine for differentiated thyroid cancer is the original theranostic pair, in clinical use since the 1940s. Iodine-123 or low-dose iodine-131 images thyroid tissue, and higher-dose iodine-131 ablates it. The current wave of agents applies the same principle to targets identified through modern molecular biology.

The operational implications reach beyond radiology. Theranostics requires coordination between nuclear medicine, medical oncology, and radiation safety; dosimetry to calculate delivered dose; and facilities equipped to handle therapeutic radioisotopes and manage patients after administration. Departments building theranostics capability are building a treatment service rather than adding an imaging protocol.

Development is active across additional targets, and the field is expected to expand substantially. For where this sits in the broader trajectory of imaging, see the future of medical imaging.

Limitations

Tracer availability. Fluorine-18 has a half-life near two hours, which permits regional distribution from a production facility. Carbon-11 has a half-life near twenty minutes, requiring an on-site cyclotron. Tracer choice is therefore constrained by geography and infrastructure as much as by clinical need.

Cost and reimbursement. PET/CT and PET/MRI systems carry high capital and operating costs, and tracer costs per study are high. Reimbursement varies by indication and jurisdiction, and coverage frequently lags clinical evidence.

Specificity. FDG uptake reflects metabolic activity generally rather than malignancy specifically, so inflammation, infection, and healing tissue all produce uptake. Interpretation depends on pattern recognition and clinical correlation rather than uptake alone.

Radiation dose. Molecular imaging involves internal radiation exposure from the administered tracer, which is a genuine consideration in younger patients and in protocols requiring serial imaging.

Standardization. Quantitative measures including standardized uptake value are sensitive to acquisition timing, patient preparation, reconstruction parameters, and scanner calibration. Comparison across sites and across time requires protocol discipline that is not universally maintained.

For how the underlying technology developed to this point, see the evolution of medical imaging.

Frequently asked questions

What is molecular imaging?

Molecular imaging visualizes biological processes at the cellular and molecular level rather than anatomical structure. It uses tracers designed to bind specific molecular targets, labeled so a scanner can detect where they accumulate. The main clinical modalities are PET and SPECT, with molecular MRI and optical imaging in more limited roles.

What is the difference between molecular imaging and anatomical imaging?

Anatomical imaging shows structure: size, shape, position, and structural abnormality. Molecular imaging shows biology: metabolic activity, receptor expression, protein deposition. A CT shows that a mass exists. A PET scan shows whether it is metabolically active. The two are complementary and frequently acquired together on hybrid PET/CT or PET/MRI systems.

What is the difference between PET and SPECT?

PET detects coincident photon pairs produced when a positron annihilates with an electron, which gives higher sensitivity and better spatial resolution. SPECT detects single gamma photons using physical collimation that absorbs most emitted photons, giving lower sensitivity. SPECT uses cheaper, longer-lived isotopes and remains standard for myocardial perfusion and bone imaging. Tracer availability usually determines which is used.

What is theranostics?

Theranostics pairs a diagnostic tracer with a therapeutic agent targeting the same molecular structure. Imaging confirms the target is present, then the therapeutic version delivers radiation to those sites. Lutetium-177 DOTATATE for neuroendocrine tumors and lutetium-177 PSMA for prostate cancer are current examples. Radioactive iodine for thyroid cancer is the original application.

What is PSMA PET used for?

PSMA PET images prostate-specific membrane antigen, expressed at high density on prostate cancer cells. It is used for staging in higher-risk disease, for localizing recurrence when PSA rises after treatment, and for selecting patients for PSMA-targeted therapy. It detects recurrence at PSA levels where conventional imaging typically shows nothing.

Is molecular imaging safe?

Molecular imaging involves internal radiation exposure from the administered tracer, with doses comparable to other nuclear medicine procedures. Tracer reactions are rare. The exposure is weighed against diagnostic benefit, with additional consideration in younger patients, pregnancy, and protocols requiring repeated imaging.

What is a tracer?

A tracer is a molecule designed to bind a specific biological target, labeled with an isotope the scanner can detect. The targeting molecule determines what the study shows. FDG targets glucose metabolism, PSMA tracers target prostate cancer cells, and amyloid tracers target plaque in the brain. Molecular imaging’s clinical range is determined by which tracers are available and validated.

How long does a PET scan take?

Most PET studies involve an uptake period after tracer administration, commonly around 60 minutes for FDG, during which the patient rests, followed by 20 to 40 minutes of scanning. Total appointment time is typically two to three hours. Preparation requirements, including fasting, vary by tracer and indication.

Conclusion

Molecular imaging reaches questions that structural imaging cannot answer: whether tissue is metabolically active, whether it expresses a therapeutic target, whether it is responding to treatment before it has changed size. The field’s clinical reach is set by tracer development rather than scanner capability, which is why PSMA and somatostatin receptor agents changed practice more than any hardware advance of the same period.

Theranostics extends this further by making the imaging study determinative of treatment. When the diagnostic scan identifies who will respond to a therapy targeting the same structure, imaging stops being purely diagnostic and becomes part of the treatment pathway.

For the wider set of imaging techniques and how they compare, see imaging modalities. For cardiac applications specifically, see nuclear cardiology.